Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2023.1253552 Oncology Correction Corrigendum: A genome-wide investigation of effects of aberrant DNA methylation on the usage of alternative promoters in hepatocellular carcinoma Dong Yuting 1 2 3 † Liu Xiaozhao 1 2 3 † Jiang Bijun 1 2 3 Wei Siting 1 2 3 Xiang Bangde 4 Liao Ruichu 1 2 3 Wang Qiuyan 5 6 * He Ximiao 1 2 3 * 1 Department of Physiology, School of Basic Medical Science, Huazhong University of Science and Technology, Wuhan, China 2 Center for Genomics and Proteomics Research, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 3 Hubei Key Laboratory of Drug Target Research and Pharmacodynamic Evaluation, Huazhong University of Science and Technology, Wuhan, China 4 Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, China 5 Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China 6 Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi, Collaborative Innovation Center for Genomic and Personalized Medicine, Nanning, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Ximiao He, XimiaoHe@hust.edu.cn; Qiuyan Wang, wangqiuyan@gxmu.edu.cn

†These authors have contributed equally to this work

 31 08 2023 2023 13 1253552 05 07 2023 06 07 2023 Copyright © 2023 Dong, Liu, Jiang, Wei, Xiang, Liao, Wang and He 2023 Dong, Liu, Jiang, Wei, Xiang, Liao, Wang and He

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on A genome-wide investigation of effects of aberrant DNA methylation on the usage of alternative promoters in hepatocellular carcinoma. by Dong Y, Liu X, Jiang B, Wei S, Xiang B, Liao R, Wang Q and He X (2022) Front. Oncol. 11:780266. doi: 10.3389/fonc.2021.780266 hepatocellular carcinoma alternative promoters DNA methylation diagnostic model survival prediction section-in-acceptance Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

In the published article, there was an error in the legend for Supplementary Figures 6M, N. The sample correlation clustering was performed using “promoter activity” instead of “WGBS”. The correct material statement appears below.

(M) Heatmap shows the correlation of three pairs of promoter activity in GSE70091.

(N) Heatmap shows the better performance correlation of two pairs of promoter activity in GSE70091 after removing N3 and T3 pairs.

In the published article, there was a typographical error. The gene name “RABGAP1L” was mistakenly written as “RABGAPL1”.

A correction has been made to Results, The Methylation Regulated APs Could Be Used as Tumor Diagnostic Markers, Paragraph 1. This sentence previously stated:

“The six mrAPs were clustered into four upregulated mrAPs (prmtr.53735 of TNFRSF10, prmtr.32651 of RGS3, prmtr.36049 of CCDC150, and prmtr.5237 of RASSF1) and two downregulated mrAPs (prmtr.37640 of TACC1 and prmtr.39585 of RABGAPL1) by promoter activities (Figure 4D, upper; Table 1; Table S5).”

The corrected sentence appears below:

“The six mrAPs were clustered into four upregulated mrAPs (prmtr.53735 of TNFRSF10, prmtr.32651 of RGS3, prmtr.36049 of CCDC150, and prmtr.5237 of RASSF1) and two downregulated mrAPs (prmtr.37640 of TACC1 and prmtr.39585 of RABGAP1L) by promoter activities (Figure 4D, upper; Table 1; Table S5).”

According to the guidelines of Ethics Statement, the authors replaced the previous statement “Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article” with the following statement.

“The studies involving humans were approved by the Ethics Committee of Guangxi Medical University Cancer Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.”

The authors apologize for these errors and amendments and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.